RT Journal Article
SR Electronic
T1 Initial experience with short-course corticosteroids in a small cohort of adults with severe COVID-19 in a tertiary care hospital in India
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.23.20137471
DO 10.1101/2020.06.23.20137471
A1 Jha, Sanjiv
A1 Shetty, Kiran
A1 Vadi, Sonali
A1 Phadtare, Sourabh
A1 Kothari, Vatsal
A1 Raut, Abhijit
A1 Shah, Sweta
A1 Bhargava, Pallavi
A1 Singhal, Tanu
YR 2020
UL http://medrxiv.org/content/early/2020/06/24/2020.06.23.20137471.1.abstract
AB Severe COVID 19 disease is associated with high morbidity and mortality with limited therapeutic options. The role of glucocorticoids in treatment of COVID 19 has been riddled with controversy. The study site has been using glucocorticoids in patients with severe COVID 19 since the first few patients of COVID 19 that were admitted. In the initial cohort of 7 patients with severe COVID disease, use of methylprednisolone in a dose of 30 mg twice daily was associated with rapid improvement in oxygenation and decline in CRP levels. While six patients made a complete clinical recovery, one patient died. There were no secondary infections.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Research and Ethics CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw data is archived with the medical records department of kokilaben hospital